Baidu
map

J Med Virol:治疗前患者状况、AFP水平、RBV/体重(BW)比可作为sofosbuvir联合Ribavirin治疗HCV基因2型患者效果的独立预测因

2018-02-06 MedSci MedSci原创

RBV联合SOF治疗HCV基因2型感染患者,SVR率高且安全性高。联合治疗后,患者血清AFP水平降低,患者肝脏硬度得到改善,但控制衰减参数上升

虽然利巴韦林(RBV)和索非布韦(SOF)的联合治疗对HCV基因2型患者的治疗是有效的,但治疗效果和治疗后甲胎蛋白(AFP)、肝硬度改变的预测因素,目前并不清楚。

本研究中纳入302例HCV基因2型患者,这些患者接受12周的SOF和RBV联合治疗。在基线和治疗结束的48周内分析治疗的效果和安全性,以及检测患者血清AFP水平、肝硬化和控制衰减参数(CAP,脂肪变性的替代指标)。

患者整体上的可持续病毒学应答率为97.5%。没有1例患者因为药物不良反应终止治疗。多元分析表明,治疗前患者状况(无干扰素治疗),AFP水平(AFP;<10 mug/l),RBV/体重(BW)比(≥9.0 mg/kg)作为SVR的独立预测因子。有两项预测因素不佳(AFP >/=10 mug/l和RBV/BW <9.0 mg/kg)的患者,相比其他患者,可持续病毒学应答率显著降低。获得可持续病毒学应答的患者,治疗后甲胎蛋白水平和肝硬度水平相比基线显著降低。所有患者中,治疗后的控制衰竭参数较基线水平要高。

RBV联合SOF治疗HCV基因2型感染患者,SVR率高且安全性高。联合治疗后,患者血清AFP水平降低,患者肝脏硬度得到改善,但控制衰减参数上升。

原始出处

Ohya K, Akuta N, Suzuki F, et al. Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2. J Med Virol, 2018, Jan 5. doi: 10.1002/jmv.25023.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1633258, encodeId=05c0163325889, content=<a href='/topic/show?id=08a220e6ce' target=_blank style='color:#2F92EE;'>#AFP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2076, encryptionId=08a220e6ce, topicName=AFP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b922043063, createdName=mxj1971619, createdTime=Sun Nov 11 00:13:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793351, encodeId=90aa1e93351d2, content=<a href='/topic/show?id=b614154551f' target=_blank style='color:#2F92EE;'>#Ribavirin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15455, encryptionId=b614154551f, topicName=Ribavirin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Sep 22 22:13:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077370, encodeId=b6bd20e73706e, content=<a href='/topic/show?id=cb141845040' target=_blank style='color:#2F92EE;'>#Virol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18450, encryptionId=cb141845040, topicName=Virol)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Thu May 24 22:13:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037808, encodeId=4628203e80893, content=<a href='/topic/show?id=852341665f0' target=_blank style='color:#2F92EE;'>#基因2型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41665, encryptionId=852341665f0, topicName=基因2型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Sun May 06 17:13:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257714, encodeId=3353125e71467, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Thu Feb 08 12:13:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500788, encodeId=90b21500e8887, content=<a href='/topic/show?id=4a27165246a' target=_blank style='color:#2F92EE;'>#Sofosbuvir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16524, encryptionId=4a27165246a, topicName=Sofosbuvir)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50d29462111, createdName=Tommy1952, createdTime=Thu Feb 08 12:13:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608539, encodeId=e6d216085396f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Feb 08 12:13:00 CST 2018, time=2018-02-08, status=1, ipAttribution=)]
    2018-11-11 mxj1971619
  2. [GetPortalCommentsPageByObjectIdResponse(id=1633258, encodeId=05c0163325889, content=<a href='/topic/show?id=08a220e6ce' target=_blank style='color:#2F92EE;'>#AFP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2076, encryptionId=08a220e6ce, topicName=AFP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b922043063, createdName=mxj1971619, createdTime=Sun Nov 11 00:13:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793351, encodeId=90aa1e93351d2, content=<a href='/topic/show?id=b614154551f' target=_blank style='color:#2F92EE;'>#Ribavirin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15455, encryptionId=b614154551f, topicName=Ribavirin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Sep 22 22:13:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077370, encodeId=b6bd20e73706e, content=<a href='/topic/show?id=cb141845040' target=_blank style='color:#2F92EE;'>#Virol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18450, encryptionId=cb141845040, topicName=Virol)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Thu May 24 22:13:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037808, encodeId=4628203e80893, content=<a href='/topic/show?id=852341665f0' target=_blank style='color:#2F92EE;'>#基因2型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41665, encryptionId=852341665f0, topicName=基因2型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Sun May 06 17:13:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257714, encodeId=3353125e71467, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Thu Feb 08 12:13:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500788, encodeId=90b21500e8887, content=<a href='/topic/show?id=4a27165246a' target=_blank style='color:#2F92EE;'>#Sofosbuvir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16524, encryptionId=4a27165246a, topicName=Sofosbuvir)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50d29462111, createdName=Tommy1952, createdTime=Thu Feb 08 12:13:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608539, encodeId=e6d216085396f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Feb 08 12:13:00 CST 2018, time=2018-02-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1633258, encodeId=05c0163325889, content=<a href='/topic/show?id=08a220e6ce' target=_blank style='color:#2F92EE;'>#AFP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2076, encryptionId=08a220e6ce, topicName=AFP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b922043063, createdName=mxj1971619, createdTime=Sun Nov 11 00:13:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793351, encodeId=90aa1e93351d2, content=<a href='/topic/show?id=b614154551f' target=_blank style='color:#2F92EE;'>#Ribavirin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15455, encryptionId=b614154551f, topicName=Ribavirin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Sep 22 22:13:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077370, encodeId=b6bd20e73706e, content=<a href='/topic/show?id=cb141845040' target=_blank style='color:#2F92EE;'>#Virol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18450, encryptionId=cb141845040, topicName=Virol)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Thu May 24 22:13:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037808, encodeId=4628203e80893, content=<a href='/topic/show?id=852341665f0' target=_blank style='color:#2F92EE;'>#基因2型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41665, encryptionId=852341665f0, topicName=基因2型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Sun May 06 17:13:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257714, encodeId=3353125e71467, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Thu Feb 08 12:13:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500788, encodeId=90b21500e8887, content=<a href='/topic/show?id=4a27165246a' target=_blank style='color:#2F92EE;'>#Sofosbuvir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16524, encryptionId=4a27165246a, topicName=Sofosbuvir)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50d29462111, createdName=Tommy1952, createdTime=Thu Feb 08 12:13:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608539, encodeId=e6d216085396f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Feb 08 12:13:00 CST 2018, time=2018-02-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1633258, encodeId=05c0163325889, content=<a href='/topic/show?id=08a220e6ce' target=_blank style='color:#2F92EE;'>#AFP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2076, encryptionId=08a220e6ce, topicName=AFP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b922043063, createdName=mxj1971619, createdTime=Sun Nov 11 00:13:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793351, encodeId=90aa1e93351d2, content=<a href='/topic/show?id=b614154551f' target=_blank style='color:#2F92EE;'>#Ribavirin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15455, encryptionId=b614154551f, topicName=Ribavirin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Sep 22 22:13:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077370, encodeId=b6bd20e73706e, content=<a href='/topic/show?id=cb141845040' target=_blank style='color:#2F92EE;'>#Virol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18450, encryptionId=cb141845040, topicName=Virol)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Thu May 24 22:13:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037808, encodeId=4628203e80893, content=<a href='/topic/show?id=852341665f0' target=_blank style='color:#2F92EE;'>#基因2型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41665, encryptionId=852341665f0, topicName=基因2型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Sun May 06 17:13:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257714, encodeId=3353125e71467, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Thu Feb 08 12:13:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500788, encodeId=90b21500e8887, content=<a href='/topic/show?id=4a27165246a' target=_blank style='color:#2F92EE;'>#Sofosbuvir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16524, encryptionId=4a27165246a, topicName=Sofosbuvir)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50d29462111, createdName=Tommy1952, createdTime=Thu Feb 08 12:13:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608539, encodeId=e6d216085396f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Feb 08 12:13:00 CST 2018, time=2018-02-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1633258, encodeId=05c0163325889, content=<a href='/topic/show?id=08a220e6ce' target=_blank style='color:#2F92EE;'>#AFP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2076, encryptionId=08a220e6ce, topicName=AFP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b922043063, createdName=mxj1971619, createdTime=Sun Nov 11 00:13:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793351, encodeId=90aa1e93351d2, content=<a href='/topic/show?id=b614154551f' target=_blank style='color:#2F92EE;'>#Ribavirin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15455, encryptionId=b614154551f, topicName=Ribavirin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Sep 22 22:13:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077370, encodeId=b6bd20e73706e, content=<a href='/topic/show?id=cb141845040' target=_blank style='color:#2F92EE;'>#Virol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18450, encryptionId=cb141845040, topicName=Virol)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Thu May 24 22:13:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037808, encodeId=4628203e80893, content=<a href='/topic/show?id=852341665f0' target=_blank style='color:#2F92EE;'>#基因2型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41665, encryptionId=852341665f0, topicName=基因2型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Sun May 06 17:13:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257714, encodeId=3353125e71467, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Thu Feb 08 12:13:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500788, encodeId=90b21500e8887, content=<a href='/topic/show?id=4a27165246a' target=_blank style='color:#2F92EE;'>#Sofosbuvir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16524, encryptionId=4a27165246a, topicName=Sofosbuvir)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50d29462111, createdName=Tommy1952, createdTime=Thu Feb 08 12:13:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608539, encodeId=e6d216085396f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Feb 08 12:13:00 CST 2018, time=2018-02-08, status=1, ipAttribution=)]
    2018-02-08 ymljack
  6. [GetPortalCommentsPageByObjectIdResponse(id=1633258, encodeId=05c0163325889, content=<a href='/topic/show?id=08a220e6ce' target=_blank style='color:#2F92EE;'>#AFP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2076, encryptionId=08a220e6ce, topicName=AFP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b922043063, createdName=mxj1971619, createdTime=Sun Nov 11 00:13:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793351, encodeId=90aa1e93351d2, content=<a href='/topic/show?id=b614154551f' target=_blank style='color:#2F92EE;'>#Ribavirin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15455, encryptionId=b614154551f, topicName=Ribavirin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Sep 22 22:13:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077370, encodeId=b6bd20e73706e, content=<a href='/topic/show?id=cb141845040' target=_blank style='color:#2F92EE;'>#Virol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18450, encryptionId=cb141845040, topicName=Virol)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Thu May 24 22:13:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037808, encodeId=4628203e80893, content=<a href='/topic/show?id=852341665f0' target=_blank style='color:#2F92EE;'>#基因2型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41665, encryptionId=852341665f0, topicName=基因2型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Sun May 06 17:13:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257714, encodeId=3353125e71467, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Thu Feb 08 12:13:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500788, encodeId=90b21500e8887, content=<a href='/topic/show?id=4a27165246a' target=_blank style='color:#2F92EE;'>#Sofosbuvir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16524, encryptionId=4a27165246a, topicName=Sofosbuvir)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50d29462111, createdName=Tommy1952, createdTime=Thu Feb 08 12:13:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608539, encodeId=e6d216085396f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Feb 08 12:13:00 CST 2018, time=2018-02-08, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1633258, encodeId=05c0163325889, content=<a href='/topic/show?id=08a220e6ce' target=_blank style='color:#2F92EE;'>#AFP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2076, encryptionId=08a220e6ce, topicName=AFP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b922043063, createdName=mxj1971619, createdTime=Sun Nov 11 00:13:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793351, encodeId=90aa1e93351d2, content=<a href='/topic/show?id=b614154551f' target=_blank style='color:#2F92EE;'>#Ribavirin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15455, encryptionId=b614154551f, topicName=Ribavirin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Sep 22 22:13:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077370, encodeId=b6bd20e73706e, content=<a href='/topic/show?id=cb141845040' target=_blank style='color:#2F92EE;'>#Virol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18450, encryptionId=cb141845040, topicName=Virol)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Thu May 24 22:13:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037808, encodeId=4628203e80893, content=<a href='/topic/show?id=852341665f0' target=_blank style='color:#2F92EE;'>#基因2型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41665, encryptionId=852341665f0, topicName=基因2型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Sun May 06 17:13:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257714, encodeId=3353125e71467, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Thu Feb 08 12:13:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500788, encodeId=90b21500e8887, content=<a href='/topic/show?id=4a27165246a' target=_blank style='color:#2F92EE;'>#Sofosbuvir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16524, encryptionId=4a27165246a, topicName=Sofosbuvir)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50d29462111, createdName=Tommy1952, createdTime=Thu Feb 08 12:13:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608539, encodeId=e6d216085396f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Feb 08 12:13:00 CST 2018, time=2018-02-08, status=1, ipAttribution=)]

相关资讯

Hepatology:DAA治疗失败的基因1 型丙型肝炎患者中,Sofosbuvir-velpatasvir-voxilaprevir使用效果评估

基因1型丙型肝炎病毒(HCV)感染的患者使用直接作用抗病毒药物(DAA)方案治疗失败以后的最佳再治疗策略,目前仍然未知。近来美国学者发表研究性文章于Hepatology,在美国一个医疗中心开展的2期开放标记研究中,以往使用DAA方案未能达到SVR的基因1型丙型肝炎(HCV)患者被随机分组接受治疗 ,分别使用包含或不含利巴韦林的sofosbuvir-velpatasvir-voxilaprevir组

Eur J Gastroenterol Hepatol:Sofosbuvir、daclatasvir联合利巴韦林治疗改善慢性丙型肝炎患者肝功能

总之,研究结果表明,SOF、DCV等直接抗病毒药物联合利巴韦林治疗显著改善了慢性丙型肝炎患者肝脏功能和临床治疗效果。

吉利德泛基因型丙肝鸡尾酒疗法SOF/VEL获FDA优先审查资格,将极大简化丙肝临床治疗

丙肝巨头吉利德(Gilead)正在开发的一款泛基因型丙肝鸡尾酒疗法SOF/VEL(sofosbuvir/velpatasvir)近日在美国监管方面传来喜讯,FDA已授予该鸡尾酒疗法治疗全部6种基因型丙肝的优先审查资格,其审查周期将从常规的10个月缩短至6个月,有望使这款泛基因型丙肝鸡尾酒提前上市,造福美国广大丙肝群体。 SOF/VEL是一种日服一次的泛基因型丙肝鸡尾酒疗法,开发用于全部6种基因型

The Lancet Infectious Diseases:ledipasvir与sofosbuvir联用治疗HCV-HIV共感染患者

6周的ledipasvir与sofosbuvir联合治疗对HCV-HIV共感染病人的治愈率与先前的干扰素治疗方案相近,但治疗时间大幅缩短并且治疗副作用更小

NEJM:3D疗法用于各型先前治疗失败的HCV感染者

Sofosbuvir–velpatasvir–voxilaprevir 治疗12周可有效提高先前DAA治疗失败的各型HCV感染者的治愈率

J Viral Hepat:采用Sofosbuvir和Ribavirin治疗后,青少年HCV患者生活质量发生怎样的改变?

患有HCV的青少年在接受SOF+RBV治疗过程中似乎并没有经历任何HRQL的损害,在获得SVR后,他们的HRQL评分也有所提高

Baidu
map
Baidu
map
Baidu
map